Exploring Hyperbaric Oxygen Therapy as a Potential Treatment for Long COVID
Hyperbaric oxygen therapy is being explored as a long COVID treatment. Here’s what the research shows
Scientificamerican
Image: Scientificamerican
Hyperbaric oxygen therapy (HBOT) is being investigated as a treatment for long COVID, showing mixed results in clinical studies. While some patients report significant improvements in cognitive function and quality of life, others experience no benefits or even adverse effects. Access to HBOT remains limited due to cost and regulatory barriers.
- 01M. Martinez experienced significant cognitive recovery after eight weeks of HBOT, returning to work and driving.
- 02Clinical trials show inconsistent results; a study in Israel found lasting benefits, while a Swedish trial showed no advantage over placebo.
- 03HBOT may help long COVID patients with vascular dysfunction or neuroinflammation, but more research is needed to identify the most suitable candidates.
- 04The therapy is not FDA-approved for long COVID, and insurance coverage is unlikely without further large-scale trials.
- 05Costs for HBOT are high, with a full course potentially exceeding $200,000, limiting access to those who can afford it.
Advertisement
In-Article Ad
Hyperbaric oxygen therapy (HBOT) is being explored as a treatment for long COVID, a condition affecting millions with symptoms like brain fog and fatigue. M. Martinez, a patient who underwent HBOT, saw significant improvements in cognitive function after eight weeks. The therapy involves breathing pure oxygen in a pressurized chamber and is known to aid conditions like decompression sickness. However, the evidence for its effectiveness in treating long COVID is mixed. A trial in Israel reported lasting cognitive and energy improvements, while a Swedish study found no benefits compared to placebo. Experts suggest HBOT may be beneficial for patients with specific vascular or neuroinflammatory issues, but further research is necessary to determine optimal treatment protocols. Despite its potential, HBOT is not FDA-approved for long COVID, and high costs pose significant barriers to access, as treatments can reach up to $200,000. Without insurance coverage or large-scale clinical trials, access to this therapy remains limited, raising equity concerns for those affected by long COVID.
Advertisement
In-Article Ad
The potential use of HBOT for long COVID could significantly affect treatment options for patients suffering from this condition.
Advertisement
In-Article Ad
Reader Poll
What is your opinion on the use of hyperbaric oxygen therapy for long COVID treatment?
Connecting to poll...
Read the original article
Visit the source for the complete story.